Helix BioMedix Announces Positive Results of Anti-Wrinkle Study Apr 27, 2004 - Bothell, Washington
Helix BioMedix (OTC Bulletin Board: HXBM.OB - News) today announced that it has completed a 12-week
consumer product test comparing the company's anti-wrinkle peptide, HB168 with Renova@, a currently
marketed FDA approved product. DermDx, an independent, physician-run center for dermatology,
conducted the study. The peptide demonstrated equivalence to Renova@ without the irritation associated
HB168 reduced the appearance of fine lines and wrinkles around the eyes in 69 percent of the subjects, with
a marked or moderate improvement in 35 percent of the subjects. These results compare favorably with the
results experienced by those using Renova@: 69 percent showed improvement and 27 percent showed
marked or moderate improvement. Of significance is that HB168 produced these results without causing
irritation. Irritation is a major issue in the skin care industry. For example, Renova@, a well-respected
industry leader, states on its label that it has shown to cause such adverse reactions as peeling, redness
and dry skin. Over 25 percent of study participants commented on irritation caused by the use of Renova@
yet no subjects reported any of these effects while using the HB168 peptide. The subjects of the trial ranged
"These results further validate the company's technology in the application of cost effective Helix BioMedix
peptides for skin care products," stated R. Stephen Beatty, President & CEO. "Helix continues to build its
successful skin care program, this being the fourth successful human panel study. The anti-wrinkle skin care
market is approximately a $2 billion a year market and is estimated to grow 16% each year. We expect the
use of peptides to help fuel that growth. This peptide is one of several that we are currently developing,
including those with application in acne care, oral care, and deodorant."
Many major cosmetic companies recognize the benefits of peptides and are beginning to use them in skin
care product lines. Director of Business Development, David Drajeske stated, "Helix has ongoing
discussions with several companies, which have been awaiting these results since we released our
preliminary findings of this study. This peptide may enable exciting new products for companies that
specialize in skin care and wrinkle reduction."
The study's results were graded by a five member independent panel, including a dermatologist and a
plastic surgeon. All investigators rated the peptide equal to or more effective than Renova@ cream in regard
to therapy for fine lines and wrinkles about the eye. Dr. Stephen Schleicher, Director of DermDx,
commented, "Based on these findings, the HB168 peptide shows promise as a topical anti-aging
About Helix BioMedix:
Helix BioMedix, Inc. is an early-stage biotechnology company whose mission is to become the industry
leader in developing and commercializing bioactive peptides, which are small proteins. The antimicrobial
and wound healing properties of these peptides qualify them for inclusion in a wide range of both
pharmaceutical and consumer products. The company is currently focused on the development of selected
peptides as pharmaceutical agents for use as topical anti-infectives and in wound healing. Non-
pharmaceutical applications being pursued by Helix BioMedix include adjuvants for
cosmetics/cosmeceuticals, personal care, plant health, animal health and wide-spectrum biocides. More
information about the company and its proprietary peptides can be found on the company's website at
Statements made in this press release relating to Helix BioMedix's future growth potential are forward-
looking and actual results could differ materially. Among other things, Helix BioMedix's future growth
potential could be impacted by a number of factors, including competition, pricing, the ability to supply
product, product withdrawals, new product approvals and launches, unanticipated expenses such as
litigation or legal settlement expenses or equity securities write-down, costs of sales, R&D expenses,
fluctuations in contract revenues and royalties, and fluctuations in tax and interest rates.

The Commonwealth of Massachusetts Executive Office of Health and Human Services 250 Washington Street, Boston, MA 02108-4619 Updated August 25, 2009 Staying Home with the Flu: Instructions for Those Who Are Sick and Their Close Contacts Dear Flu Sufferer, You are suspected of having flu or have been diagnosed with flu. To help prevent the spread of flu virus to others,